ESTRADIOL-RECEPTOR ACTIVITY IN HUMAN-BREAST CANCER, DISEASE FREE INTERVAL AND SURVIVAL-TIME

  • 1 January 1982
    • journal article
    • research article
    • Vol. 2  (1-2) , 33-36
Abstract
Disease-free interval and survival time of breast cancer patients were investigated in regard to the estradiol receptor (ER) status as measured in the corresponding primary tumors. Disease-free interval and survival time of patients with ER positive breast cancers were significantly longer than those of patients with ER negative tumors. The percentage of ER positive tumors in patients with finished free interval, or that died as a consequence of their disease, is lower than that found in an unselected material. The ER concentrations did not, however, differ significantly. Patients with ER positive breast cancers of stage IV did not survive longer than patients with ER negative tumors. No correlations were between disease-free interval and survival time of the patients, and the ER concentrations measured in their corresponding tumors individually. The menopausal status of the patients influenced the disease free interval regardless of the ER status of the primary tumors. The survival time of postmenopausal patients with ER positive breast cancers were significantly longer than that of premenopausal patients with ER negative cancers. The average ER concentration of breast cancers of postmenopausal patients with finished free interval is significantly higher than the value found in cancers of premenopausal patients.